Figure 5.

Gilteritinib activates GSK3β and inhibits AKT to induce PUMA through p65 activation. A, HCT116 cells were transfected with either a control scrambled siRNA or a GSK3β siRNA for 24 h, and then treated with 50 nmol/L gilteritinib for 24 h. Indicated proteins were analysed by Western blotting. B, HCT116 and RKO cells treated with 50 nmol/L gilteritinib for 24 h. The levels of total GSK3β and p‐GSK3β (S9) were analysed by Western blotting. C, HCT116 cells treated with 50 nmol/L gilteritinib at indicated time‐points. The levels of total AKT and p‐AKT were analysed by Western blotting. D, HCT116 cells transfected with AKT were treated with 50 nmol/L gilteritinib for 24 h. Indicated proteins were analysed by Western blotting